Following steady improvements in survival rates, there is a growing interest in establishing the long-term side effects of cancer treatments. This includes a need for a better understanding of the cognitive safety profile of these interventions, particularly in children and adolescents. In this article, we demonstrate that CANTAB computerised assessments offer a sensitive and practical solution for assessing cognitive function in oncology trials.
Dr Thomas Johansen from the Norwegian National Advisory Unit on Occupational Rehabilitation talked us through why he chose CANTAB to investgate whether improving cognitive function during occupational rehabilitation improves return to work.
Dr Seán Haldane is a Consultant Neuropsychologist and expert witness who provides reports for defence lawyers, the Crown Prosecution Service and the police. We caught up with Dr Haldane to discuss how CANTAB Insight is integral to his work.
We presented a novel, predictive model of functional decline at CTAD 2018. The model suggests that CANTAB PAL and SWM provide essential screening information when recruiting patients with amnestic mild cognitive impairment into Alzheimer’s disease clinical trials.
We caught up with University of Calgary Postdoctoral Research Fellows, Dr Matiram Pun and Dr Veronica Guadagni, to discuss the role of CANTAB in their recent research paper on how different exposures to high altitude affect cognitive function.
We caught up with Shinwon Park at Ewha Womens University to discuss their experiences of updating their longitudinal studies from tablet-only CANTAB Eclipse to the cloud-based CANTAB Connect Research platform.
PhD researcher, Rosalyn Hithersay, spoke to us about her recent publication on which cognitive tests are most sensitive to the early stages of dementia in Down syndrome.
We are very pleased to announce a planned new software product to assess mental health and wellbeing at work, CANTAB BrainHealth™.
With rising life-expectancy, the number of cases of dementia and related disorders is increasing. In attempts to tackle the pandemic, treatment trials are moving earlier in the disease process. CANTAB offers a battery of tests specially targeted at assessing cognition in early Alzheimer’s disease (AD), and the associated effects on cognition with drug action.
Published in Drug Discovery Today, our keynote review outlines the rationale, study design, and methods for cognitive safety assessment during clinical drug development.
Mood disorders affect 5-10% of the adult population in a given year. The most common mood disorders are major depressive disorder, dysthymia, and bipolar disorder. Here we explore the six CANTAB tests for objectively measuring cognitive function in depression.
Cognition is essential for everyday functioning - here's why.